Search Within

Bone Marrow Transplant

Formats
  1. Meeting Abstract (1531)
  2. Journal Article (1198)
  3. Review (75)
  4. Research Letter (49)
  5. Book Section (34)
  6. Guidelines (26)
  7. Editorial (24)
  8. Correspondence (18)
  9. Conference Paper (14)
  10. Book Whole (1)
  11. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (2971)
  2. Department of Medicine (2971)
  3. Hematologic Malignancies, Division of (2848)
  4. Survivorship Research (1389)
  5. GSK Faculty (931)
  6. CTCR Scholars (874)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Sean Devlin (470)
  4. Ann Jakubowski (459)
  5. Gunjan Shah (447)
  6. Heather Landau (436)

More People

Years
  1. 2025 (68)
  2. 2024 (212)
  3. 2023 (263)
  4. 2022 (201)
  5. 2021 (177)
  6. 2020 (208)

More Years

Publications
  1. Blood (887)
  2. Biology of Blood and Marrow Transplantation (516)
  3. Bone Marrow Transplantation (175)
  4. Journal of Clinical Oncology (127)
  5. Transplantation and Cellular Therapy (113)
  6. Blood Advances (95)

More Publications

Publishers
  1. American Society of Hematology (989)
  2. Elsevier Inc. (767)
  3. Nature Publishing Group (261)
  4. American Society of Clinical Oncology (130)
  5. Wiley Blackwell (66)
  6. Taylor & Francis Group (65)

More Publishers

Results (2971)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The incidence and impact of clostridioides difficile infection (CDI) on outcomes after allogeneic hematopoietic cell transplant (alloHCT) - a CIBMTR study
    Meeting Abstract

    Ramanathan, M.; Savani, B. B.; He, N. Y.; Kim, S.; Chen, M.; Chemaly, R.; Dandoy, C. E.; Perales, M. A.; Riches, M. L.; Ustun, C.
    Blood (2021)

    Fulltext@MSK | Save
  • A multicenter analysis of outcomes, toxicities, and patterns of use with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas
    Meeting Abstract

    Riedell, P. A.; Brower, J.; Nastoupil, L.; Perales, M. A.; Maziarz, R. T.; McGuirk, J. P.; Bachanova, V.; Hwang, W. T.; Schuster, S. J.; Bishop, M. R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of allogeneic hematopoietic cell transplantation (HCT) as consolidation following CD19 chimeric antigen receptor (CAR) T cell therapy for treatment of relapsed acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Park, J. H.; Nikiforow, S.; Kim, S.; Hu, Z. H.; Moskop, A.; Ahmed, S.; Abid, M. B.; Badar, T.; Bredeson, C.; Brown, V.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Graded cardiac response criteria for AL amyloidosis: The impact of depth of cardiac response on survival
    Meeting Abstract

    Muchtar, E.; Dispenzieri, A.; Wisniowski, B.; Palladini, G.; Milani, P.; Merlini, G.; Schönland, S.; Veelken, K.; Hegenbart, U.; Kumar, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Graded renal response criteria for light chain (AL) amyloidosis
    Meeting Abstract

    Muchtar, E.; Wisniowski, B.; Palladini, G.; Milani, P.; Merlini, G.; Schönland, S.; Veelken, K.; Hegenbart, U.; Dispenzieri, A.; Kumar, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplantation (SCT)
    Meeting Abstract

    Mishra, A.; Tamari, R.; DeZern, A. E.; Byrne, M. T.; Gooptu, M.; Chen, Y. B.; Deeg, H. J.; Gallacher, P.; Wennborg, A.; Hickman, D. K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Post-transplant inotuzumab ozogamicin for acute lymphoblastic leukemia
    Meeting Abstract

    Metheny, L. 3rd; Sobecks, R. M.; Cho, C.; Caimi, P. F.; Majhail, N. S.; Otegbeye, F.; Boughan, K. M.; Cooper, B. W.; Galloway, E.; Gallogly, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim results of a pilot, prospective, randomized, double-blinded, vehicle- and comparator-controlled trial on safety and efficacy of a topical inhibitor of janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non- sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease
    Meeting Abstract

    Markova, A.; Pan, A.; Dusza, S.; Chowdhury, A.; Kukoyi, O.; Perales, M. A.; Lacouture, M.; Prockop, S.; Ponce, D. M.
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save